Scleroderma: Hardening and Tightening of the Skin

Clinical Overview

Systemic sclerosis (scleroderma) represents a chronic, multisystem autoimmune disease characterized by excessive fibrosis of skin and internal organs including lungs, heart, kidneys, and gastrointestinal tract. The condition demonstrates variable clinical course and severity, with cutaneous and systemic manifestations dominating clinical presentation and determining morbidity and mortality. Limited cutaneous systemic sclerosis (lcSSc) previously termed limited scleroderma or CREST syndrome demonstrates relatively favorable prognosis compared to diffuse cutaneous systemic sclerosis (dcSSc) with more aggressive skin involvement and earlier internal organ disease. Raynaud phenomenon frequently precedes scleroderma by months to years, providing opportunity for early recognition and preventive intervention. Progressive skin fibrosis leads to contractures, significant disability, and functional impairment, particularly affecting face, hands, and extremities. Interstitial lung disease (ILD) represents most common pulmonary manifestation and major cause of morbidity and mortality. Renal crisis with acute renal failure occurs in 5-10% of dcSSc patients and represents medical emergency requiring urgent intervention. Modern immunosuppressive and targeted pharmacologic approaches have substantially improved outcomes compared to historical data.

Epidemiology

Systemic sclerosis demonstrates incidence of 1-2 cases per 100,000 population annually, with prevalence estimates of 50-300 per million. Females demonstrate 4-8 fold higher incidence compared to males, with female:male ratio approaching 4:1. Peak incidence occurs in 30-50 year age group, though disease can present at any age. Caucasians demonstrate higher incidence compared to African Americans or Hispanics in most series, though genetic factors and diagnostic bias may contribute. Approximately 80% of patients present with limited cutaneous disease (lcSSc), while 20% present with diffuse cutaneous involvement (dcSSc). Anti-centromere antibody (ACA) positive patients typically demonstrate lcSSc phenotype with favorable prognosis. Anti-topoisomerase I (anti-Scl-70) antibody positive patients typically demonstrate dcSSc phenotype with more aggressive disease. Environmental exposures including vinyl chloride, silica, and organic solvents show associations with scleroderma development in occupationally exposed populations. Genetic predisposition demonstrated through HLA associations and familial clustering reported in fewer than 2% of cases.

Pathophysiology

Systemic sclerosis develops through complex interplay of autoimmune activation, endothelial cell injury, and fibroblast dysregulation leading to excessive collagen deposition in multiple organs. Initial endothelial injury occurs through immune complex deposition, complement activation, and direct T-lymphocyte mediated mechanisms, increasing vascular permeability and initiating inflammatory cascade. Activated endothelial cells express adhesion molecules promoting T-lymphocyte infiltration and activation. Vasoconstriction mediated through imbalance of endothelin-1 (vasoconstrictor) and nitric oxide/prostacyclin (vasodilators) contributes to Raynaud phenomenon and tissue ischemia. Fibroblast activation occurs through multiple mechanisms including TGF-beta signaling, direct endothelial cell-fibroblast interaction, and monocyte-derived mediators. Activated fibroblasts and myofibroblasts increase collagen synthesis dramatically, with increased expression of collagen I and III in affected tissues. Tissue hypoxia from microvascular disease stimulates hypoxia-inducible factor (HIF) driving further TGF-beta production and fibroblast activation. Autoantibodies including anti-centromere antibodies and anti-topoisomerase I antibodies develop in 90% of patients, with pathogenic roles under investigation. Regulatory T-cell dysfunction and increased Th17 lymphocyte differentiation characterize immune dysregulation in systemic sclerosis. The distinction from localized morphea involves systemic vascular, immune, and fibrotic changes affecting multiple organ systems.

Clinical Presentation

Systemic sclerosis typically presents with insidious onset of Raynaud phenomenon (painful color changes with white, blue, or red appearance in fingers exposed to cold) preceding cutaneous sclerosis by months to years. Skin thickening and hardening begins distally in hands and progressively advances proximally in diffuse disease. Early skin changes include edema and non-pitting induration, progressing to taut, shiny, atrophic skin with loss of normal wrinkles. Facial involvement causes loss of normal expression with reduced mouth opening (microstomia) from perioral fibrosis, creating expressionless "mask-like" appearance. Digital ulceration affects fingertips in 30-40% of patients, causing significant pain and risk of infection or osteolysis. Telangiectasias (dilated capillaries) appear as red macules on face, hands, and lips. Limited cutaneous disease demonstrates skin involvement distal to elbows and knees with relative sparing of trunk. Diffuse cutaneous disease involves proximal extremities and trunk with rapid progression and earlier organ involvement. Interstitial lung disease manifests as progressive dyspnea, cough, and exercise intolerance occurring in 75-80% of patients. Renal crisis develops acutely with malignant hypertension and acute renal failure in 5-10% of dcSSc patients, requiring emergency treatment. Gastrointestinal involvement causes severe reflux, dysphagia, and malabsorption. Cardiac involvement manifests as arrhythmias, conduction abnormalities, and myocardial fibrosis.

Diagnosis

Diagnosis of systemic sclerosis requires integration of clinical features, serologic findings, and histopathological findings. The 2013 ACR/EULAR classification criteria incorporate skin thickness scoring, Raynaud phenomenon, nailfold capillaroscopy, and specific serology including anti-centromere and anti-topoisomerase I antibodies. Skin biopsy demonstrates markedly thickened dermal collagen with extension into subcutis, with early perivascular lymphocytic infiltration and later progressive fibrosis. Immunofluorescence reveals IgG and complement deposition in vessel walls. Serologic evaluation identifies autoantibodies in 90% of patients, with anti-centromere antibodies predicting limited disease and anti-topoisomerase I (anti-Scl-70) predicting diffuse disease. Anti-RNA polymerase III antibodies associate with risk of renal crisis. Pulmonary function testing demonstrates reduced diffusing capacity and forced vital capacity in ILD. High-resolution CT chest identifies usual interstitial pneumonia (UIP) pattern typical of scleroderma-associated ILD. Nailfold capillaroscopy reveals distorted, enlarged capillaries ("mega-capillaries") and capillary dropout characteristic of systemic sclerosis. Echocardiography assesses right ventricular function and identifies pulmonary hypertension. Barium swallow demonstrates patulous esophagus and impaired esophageal motility from smooth muscle fibrosis.

Treatment Algorithm

Treatment of systemic sclerosis requires multidisciplinary approach addressing both cutaneous manifestations and systemic complications. Skin-directed therapy includes systemic immunosuppression attempting to halt progressive fibrosis. Corticosteroids including prednisone at doses 0.5-1 mg/kg daily (typically 40-60 mg) represent initial therapy for rapidly progressive disease, though high-dose steroids (greater than 15 mg daily) increase renal crisis risk in dcSSc. Methotrexate 15-25 mg weekly (IV or oral) with folate supplementation serves as most commonly used steroid-sparing agent achieving response in 40-50% of patients. Cyclophosphamide 1-2 mg/kg daily for 3-6 months demonstrates superiority to placebo for skin disease in clinical trials. Mycophenolate mofetil 1-3 grams daily represents alternative with emerging evidence of efficacy. Interstitial lung disease requires aggressive immunosuppression with mycophenolate mofetil 3 grams daily or cyclophosphamide pulse therapy (500-750 mg/m² monthly) achieving stabilization or improvement in 40-50% of patients. Nintedanib, a tyrosine kinase inhibitor, reduces rate of lung function decline in systemic sclerosis-associated ILD. Raynaud phenomenon management includes calcium channel blockers (nifedipine 30-60 mg daily), alpha-adrenergic antagonists (prazosin 0.5-5 mg three times daily), phosphodiesterase-5 inhibitors (sildenafil 20 mg three times daily), or endothelin receptor antagonists (bosentan 62.5 mg twice daily). Digital ulcers require local wound care and systemic vasodilators or endothelin antagonists. Renal crisis represents medical emergency requiring immediate hospitalization and aggressive antihypertensive therapy with ACE inhibitors (captopril 6.25-12.5 mg three times daily) preventing progression to end-stage renal disease. Gastrointestinal reflux management includes proton pump inhibitors (omeprazole 20 mg daily). Regular monitoring for cardiopulmonary involvement and early intervention prevent serious complications.

Prognosis

Prognosis for systemic sclerosis depends significantly on disease subset and presence of organ involvement. Limited cutaneous disease demonstrates median survival of 20+ years with appropriate management. Diffuse cutaneous disease demonstrates shorter median survival of 10-15 years, with pulmonary and renal disease representing major determinants of mortality. Five-year survival rates have improved from 60-70% historically to greater than 85% in modern series with advances in specific therapy. Interstitial lung disease develops in 75-80% of patients, with progression to respiratory failure responsible for approximately 35% of scleroderma deaths. Renal crisis, though now uncommon due to ACE inhibitor therapy, remains life-threatening with mortality rates exceeding 50% without prompt treatment. Gastrointestinal involvement contributes to morbidity through malabsorption and malnutrition but rarely directly causes death. Progressive skin fibrosis causes significant morbidity through contractures and functional impairment affecting quality of life substantially.

When to See a Dermatologist

Patients with suspected systemic sclerosis should seek dermatology evaluation for disease confirmation and initiation of appropriate therapy. Those with Raynaud phenomenon and positive ANA warrant specialist evaluation to exclude systemic sclerosis. Patients with established disease benefit from dermatology collaboration for skin-directed therapy optimization.

Frequently Asked Questions

Q: Is systemic sclerosis (scleroderma) hereditary?
A: Systemic sclerosis is not hereditary though genetic predisposition exists. Family clustering occurs in fewer than 2% of cases.

Q: Can scleroderma affect internal organs?
A: Yes, systemic sclerosis affects lungs, heart, kidneys, and gastrointestinal tract in majority of patients. Internal organ involvement represents major determinant of prognosis and mortality.

Q: Is scleroderma fatal?
A: Modern therapy has substantially improved outcomes, with 5-year survival exceeding 85%. Pulmonary and renal involvement represent major risks but are manageable with appropriate therapy.

Q: What causes Raynaud phenomenon in scleroderma?
A: Raynaud phenomenon results from excessive vasoconstriction of digital vessels triggered by cold exposure due to endothelial dysfunction and imbalance of vasodilators and vasoconstrictors.

References

  1. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699.
  2. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-205.
  3. Vettori S, Cuomo G, Abignano G, et al. Systemic sclerosis: from pathophysiology to novel therapeutic approaches. Clin Dev Immunol. 2012;2012:932501.
  4. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a population-based multicenter study. Arthritis Rheum. 2010;62(6):1659-1667.
  5. Steen VD, Medsger TA Jr. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940-944.
  6. Distler O, Allanore Y, Denton C, et al. Rheumatology in Europe: challenges and opportunities. Lancet. 2010;376(9740):454-456.
  7. Maricq HR, Weinberger AB, Keil JE, et al. Prevalence of Raynaud phenomenon in the general population. J Chronic Dis. 1986;39(6):423-427.
  8. Cutolo M, Smith V. Endothelial dysfunction in systemic sclerosis: from molecular mechanisms to vascular complications. Clin Exp Rheumatol. 2007;25(4):639-646.
  9. Whitfield ML, Finkel DJ, Murray JI, et al. Common and unique transformations in the transcriptome of fibroblasts in systemic sclerosis. BMC Genomics. 2007;8:212.
  10. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with early onset. Arthritis Rheum. 2000;43(11):2437-2445.